{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-030817","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.031477+00:00","generated_at":"2026-06-22T05:40:40.538460+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lantern Pharma Q3 2022 net loss improves to $2.3M; cash $57.8M, pipeline on track","bullets":["Net loss of $2.3M ($0.21/shr) vs $4.1M ($0.36/shr) in Q3 2021; R&D expenses fell to $0.7M.","Cash, equivalents and marketable securities $57.8M as of Sep 30, 2022; cash runway into 2025.","Harmonic Phase 2 trial (LP-300) activated first two US sites; new U.S. patent issued for LP-300 through 2032.","IND-enabling studies for LP-184 and LP-284 expected complete Q1 2023; Phase 1 launches targeted H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-030817","json":"https://secwatch.observer/filing/0001493152-22-030817.json","markdown":"https://secwatch.observer/filing/0001493152-22-030817.md","text":"https://secwatch.observer/filing/0001493152-22-030817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315222030817/0001493152-22-030817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315222030817/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:40:40.538460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4826a10a41fdfba32cab1668531def29cf98208","claim":"Lantern Pharma Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30 , 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315222030817/0001493152-22-030817-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}